Company Filing History:
Years Active: 2022
Title: Richard Martin: Innovator in Bioactive Glass Composition for Bone Cancer Treatment
Introduction
Richard Martin is a notable inventor based in Birmingham, GB. He has made significant contributions to the field of medical materials, particularly in the development of therapeutic solutions for bone cancer treatment. His innovative approach combines advanced materials science with medical applications, showcasing the potential of bioactive glass in oncology.
Latest Patents
Richard Martin holds a patent for a therapeutic material that features a bioactive glass composition specifically designed for treating bone cancer. This composition includes 0.5-10 mol % gallium oxide or 1.0-20 mol % gallium nitrate/halide, 25 to 75 mol % silicon dioxide, 10 to 30 mol % calcium oxide and/or strontium oxide, up to 30 mol % sodium oxide, and up to 15 mol % phosphorous pentoxide. Additionally, it may comprise magnesium and/or potassium oxide. The bioactive glass composition is intended to be positioned within a patient's bone post-surgery to promote apatite formation and release gallium ions, which have a toxic effect on any remaining cancerous cells. This innovative material has the potential to significantly improve treatment outcomes for patients suffering from bone cancer.
Career Highlights
Richard Martin is affiliated with Aston University, where he continues to engage in research and development in the field of bioactive materials. His work not only contributes to academic knowledge but also has practical implications for medical treatments. His dedication to innovation in therapeutic materials is evident in his patent and ongoing research efforts.
Collaborations
[This section has been skipped due to space constraints.]
Conclusion
Richard Martin's contributions to the field of bioactive glass for bone cancer treatment exemplify the intersection of innovation and healthcare. His patented work represents a significant advancement in therapeutic materials, offering hope for improved patient outcomes.